Related Experiment Video
Updated: Jul 16, 2025
09:34
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
9.0K
Janus particle-engineered structural lipiodol droplets for arterial embolization
Sijian Tao1,2, Bingquan Lin3, Houwang Zhou1
1Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, 510515, Guangzhou, P. R. China.
Nature Communications
|September 11, 2023
Summary
Janus particle-engineered lipiodol droplets offer superior embolization, effectively blocking renal arteries and finer vessels in rabbits without recanalization. This novel embolic material demonstrates enhanced stability and clinical potential.
Area of Science:
- Biomaterials Engineering
- Interventional Radiology
- Nanotechnology
Background:
- Embolization is a key treatment strategy, but current embolic materials lack sufficient effectiveness.
- Challenges remain in achieving highly efficient and durable vessel occlusion.
- Existing materials often struggle with precise delivery and long-term stability.
Purpose of the Study:
- To develop novel embolic materials with improved embolization efficiency and stability.
- To engineer structural lipiodol droplets using Janus particles for enhanced performance.
- To evaluate the efficacy of these engineered droplets in a preclinical renal embolization model.
Main Methods:
- Janus particles were used to engineer structural lipiodol droplets via self-assembly at the oil-water interface.
- The mechanical stability and viscoelastic properties of the engineered droplets were characterized.
- Renal embolization was performed in rabbits to assess efficacy, delivery, and long-term outcomes.
Main Results:
- The Janus particle-engineered droplets demonstrated excellent mechanical stability and viscoelasticity, allowing close packing for efficient arterial embolization.
- These droplets exhibited capacity for distal travel, successfully embolizing vessels as small as 40 μm.
- Post-embolization evaluation at 14 days showed no recanalization or non-target embolization, with superior effectiveness compared to clinical lipiodol emulsions.
Conclusions:
- Janus particle-engineered structural lipiodol droplets represent a significant advancement in embolic material design.
- This approach enables highly efficient renal embolization with improved stability and targeting.
- The strategy offers a promising alternative for fabricating advanced embolic agents with strong clinical application potential.
